Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on February 2, 2024, announcing its financial and operating results for the fourth quarter and full year ended December 31, 2023. The report primarily consists of a press release that details these results, which is furnished as an exhibit. Investors should refer to this press release for a comprehensive overview of the company's performance during the period. While the 8-K itself is brief, the accompanying press release (Exhibit 99.1) contains the critical financial metrics and operational updates that will be of most interest to shareholders. This includes details on revenue, earnings per share, and potentially insights into key drug performance and pipeline developments. Investors are advised to carefully review the furnished press release for specific figures and forward-looking statements.
Key Highlights
- 1Regeneron announced its Q4 and Full Year 2023 financial and operating results on February 2, 2024.
- 2The 8-K filing primarily serves to attach the press release containing the detailed results.
- 3Investors must refer to the press release (Exhibit 99.1) for specific financial figures and operational highlights.
- 4The filing indicates the company is in compliance with reporting requirements for these results.
- 5Information furnished under Item 2.02 is generally not considered 'filed' for liability purposes under Section 18 of the Exchange Act.